These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 28280262)

  • 1. Marked for death: targeting epigenetic changes in cancer.
    Pfister SX; Ashworth A
    Nat Rev Drug Discov; 2017 Apr; 16(4):241-263. PubMed ID: 28280262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
    Verma SK
    Methods Mol Biol; 2015; 1238():677-88. PubMed ID: 25421686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA methylation with small molecules: what's next?
    Erdmann A; Halby L; Fahy J; Arimondo PB
    J Med Chem; 2015 Mar; 58(6):2569-83. PubMed ID: 25406944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for the development of epigenetic drugs for CNS conditions.
    Szyf M
    Nat Rev Drug Discov; 2015 Jul; 14(7):461-74. PubMed ID: 26000723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current trends in epigenetic drug discovery.
    Stolfa DA; Einsle O; Sippl W; Jung M
    Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic polypharmacology: from combination therapy to multitargeted drugs.
    de Lera AR; Ganesan A
    Clin Epigenetics; 2016; 8():105. PubMed ID: 27752293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Discovery and Chemical Biology of Cancer Epigenetics.
    Ribich S; Harvey D; Copeland RA
    Cell Chem Biol; 2017 Sep; 24(9):1120-1147. PubMed ID: 28938089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Discovery and clinical application of mutations in the cancer genome].
    Mano H
    Nihon Rinsho; 2015 Aug; 73(8):1251-5. PubMed ID: 26281674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting epigenetic regulators for cancer therapy.
    Wee S; Dhanak D; Li H; Armstrong SA; Copeland RA; Sims R; Baylin SB; Liu XS; Schweizer L
    Ann N Y Acad Sci; 2014 Feb; 1309():30-6. PubMed ID: 24571255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methyltransferase inhibitors for cancer therapy.
    Brueckner B; Kuck D; Lyko F
    Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of DNA methyltransferase inhibitors using in silico approaches.
    Medina-Franco JL; Méndez-Lucio O; Dueñas-González A; Yoo J
    Drug Discov Today; 2015 May; 20(5):569-77. PubMed ID: 25526932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Marek M; Shaik TB; Jung M; Sippl W; Pierce RJ; Romier C
    Biol Aujourdhui; 2016; 210(4):311-320. PubMed ID: 28327287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.
    Duan YC; Zhang SJ; Shi XJ; Jin LF; Yu T; Song Y; Guan YY
    Eur J Med Chem; 2021 Oct; 222():113588. PubMed ID: 34107385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
    Barsotti AM; Ryskin M; Rollins RA
    Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
    [No Abstract]   [Full Text] [Related]  

  • 19. Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy.
    Ye BJ; Li DF; Li XY; Hao JL; Liu DJ; Yu H; Zhang CD
    Cancer Lett; 2024 Aug; 597():217010. PubMed ID: 38849016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
    Verma SK; Knight SD
    Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.